Molina JM, Capitant C, Spire
B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E,
Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P,
Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A,
Timsit J, Girard G, Lorente N, Préau M, Rooney JF, Wainberg MA, Thompson
D, Rozembaum W, Doré V, Marchand L, Simon MC, Etien N, Aboulker JP,
Meyer L, Delfraissy JF; ANRS IPERGAY Study Group. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med 2015 Dec 1. Lien PubMed
Piroth L, Paniez H, Taburet AM, Vincent C, Rosenthal E,
Lacombe K, Billaud E, Rey D, Zucman D, Bailly F, Bronowicki JP, Simony
M, Diallo A, Izopet J, Aboulker JP, Meyer L, Molina JM; ANRS
HC30 QUADRIH Study Group. High Cure Rate With 24 Weeks of
Daclatasvir-Based Quadruple Therapy in Treatment-Experienced,
Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4
Coinfection: The ANRS HC30 QUADRIH Study. Clin Infect Dis. 2015 Sep 1. Lien PubMed
Harrison L., Melvin A., Fiscus
S., Saidi Y., Nastouli E., Harper L., Compagnucci A., Babiker A.,
McKinney R., Gibb D., Tudor-Williams G. HIV-1 Drug Resistance
and Second-line Treatment in Children Randomized to Switch at Low versus
Higher RNA Thresholds. JAIDS 2015 Sept 1.Lien PubMed
INSIGHT START Study Group,
Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S,
Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi
P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN,
Neaton JD. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015 Aug 27. Lien PubMed
Gallien S, Charreau I, Nere ML, Mahjoub N, Simon F, de Castro N, Aboulker JP, Molina JM, Delaugerre C. Archived
HIV-1 DNA resistance mutations to rilpivirine and etravirine in
successfully treated HIV-1-infected individuals pre-exposed to efavirenz
or nevirapine. J Antimicrob Chemother. 2015 Feb. Lien PubMed
Cotte L, Barrail-Tran A, Vincent
C, Valantin MA, Fournier I, Lacombe K, Chevalier S, Aboulker JP,
Taburet AM, Molina JM; ANRC HC; study Group. Telaprevir enhances ribavirin-induced anaemia throught renal function impairment. Antivir Ther.2015 Jan 6. Lien PubMed